Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Short Interest Down 76.3% in May

Invesco Pharmaceuticals ETF (NYSEARCA:PJP) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totaling 792 shares, a decrease of 76.3% from the April 30th total of 3,341 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 17,047 shares, the short-interest ratio is presently 0.0 days.

Invesco Pharmaceuticals ETF Trading Down 0.8%

PJP traded down $0.86 during trading on Friday, hitting $109.63. The stock had a trading volume of 4,873 shares, compared to its average volume of 35,898. The firm has a market cap of $358.49 million, a PE ratio of 15.59 and a beta of 0.46. Invesco Pharmaceuticals ETF has a 12 month low of $78.77 and a 12 month high of $110.81. The company has a 50 day simple moving average of $105.06 and a 200-day simple moving average of $105.57.

Hedge Funds Weigh In On Invesco Pharmaceuticals ETF

Several institutional investors and hedge funds have recently added to or reduced their stakes in PJP. Jones Financial Companies Lllp increased its stake in Invesco Pharmaceuticals ETF by 11.6% in the first quarter. Jones Financial Companies Lllp now owns 2,428 shares of the company’s stock valued at $210,000 after acquiring an additional 252 shares during the period. BNP Paribas Financial Markets acquired a new stake in Invesco Pharmaceuticals ETF in the 2nd quarter valued at $799,000. Tower Research Capital LLC TRC boosted its stake in Invesco Pharmaceuticals ETF by 102.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,680 shares of the company’s stock valued at $374,000 after buying an additional 2,374 shares in the last quarter. Ameriprise Financial Inc. grew its position in Invesco Pharmaceuticals ETF by 214.4% in the third quarter. Ameriprise Financial Inc. now owns 12,236 shares of the company’s stock valued at $1,114,000 after acquiring an additional 8,344 shares during the period. Finally, Citadel Advisors LLC bought a new stake in Invesco Pharmaceuticals ETF in the third quarter valued at $504,000.

Invesco Pharmaceuticals ETF Company Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.